Investigations of methods for multiple time-to-event endpoints: A chronic myeloid leukemia data analysis

被引:1
|
作者
Wu, Hongji [1 ]
Hou, Yawen [2 ]
Chen, Zheng [1 ]
机构
[1] Southern Med Univ, Guangdong Prov Key Lab Trop Dis Res, Sch Publ Hlth, Dept Biostat, Guangzhou 510515, Peoples R China
[2] Jinan Univ, Sch Econ, Dept Stat, Guangzhou 510632, Peoples R China
基金
中国国家自然科学基金;
关键词
clinical importance; composite endpoint; hazard ratio; multiple endpoints; single endpoint; win ratio; HAZARD RATIOS; WIN RATIO; RISKS;
D O I
10.1111/jep.13752
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background In randomized controlled trials, multiple time-to-event endpoints are commonly used to determine treatment effects. However, choosing an appropriate method to address multiple endpoints, according to different purposes of clinical practice, is a challenge for researchers. Methods We applied single endpoint, composite endpoint and win ratio analysis to chronic myeloid leukemia (CML) data to illustrate the distinctions with different multiple endpoints, including relapse, recovery and death after transplantation. Results Regarding relapse and death, the hazard ratio in single endpoint analysis (HRs) were 1.281 (95% CI: 1.061-1.546) and hazard ratio in composite endpoint analysis (HRc) were 1.286 (95% CI: 1.112-1.486) and 1/WR (win ratio) was 1.292 (95% CI: 1.115-1.497) indicated a similar negative effect for non-prophylaxis patients. However, when considering recovery and death, the corresponding HRs = 1.280 (95% CI: 1.056-1.552) may not be enough to describe the effect on death with nonproportional hazards (p < 0.05), and for the composite endpoint analysis, the HRc = 0.828 (95% CI: 0.740-0.926) cannot quantify and interpret the clinical effect on the composite endpoint with the combination of recovery and death, while the 1/WR = 1.351 (95% CI: 1.207-1.513) showed an unfavourable effect for non-prophylaxis patients Conclusions When dealing with multiple endpoints, single endpoints, researchers may choose single endpoints, composite endpoints and WR analysis due to different clinical applications and purposes. However, both single and composite endpoint analyses are hazard-based measures, and thus, the proportional hazards assumption should be considered. Moreover, composite endpoint analysis should be applied for endpoints with similar clinical meanings but not opposing implications. Win ratio analysis can be considered for different clinical importance of multiple endpoints, but the meaning of 'winner' needs to be specified for desired or undesired endpoints.
引用
收藏
页码:211 / 217
页数:7
相关论文
共 50 条
  • [1] Methods for Informative Censoring in Time-to-Event Data Analysis
    Jin, Man
    Fang, Yixin
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2024, 16 (01): : 47 - 54
  • [2] Adjusted estimates for time-to-event endpoints
    Storer, Barry E.
    Gooley, Ted A.
    Jones, Michael P.
    LIFETIME DATA ANALYSIS, 2008, 14 (04) : 484 - 495
  • [3] Adjusted estimates for time-to-event endpoints
    Barry E. Storer
    Ted A. Gooley
    Michael P. Jones
    Lifetime Data Analysis, 2008, 14 : 484 - 495
  • [4] Consistency-adjusted alpha allocation methods for a time-to-event analysis of composite endpoints
    Rauch, G.
    Wirths, M.
    Kieser, M.
    COMPUTATIONAL STATISTICS & DATA ANALYSIS, 2014, 75 : 151 - 161
  • [5] Methods to Analyze Time-to-Event Data: The Cox Regression Analysis
    Abd ElHafeez, Samar
    D'Arrigo, Graziella
    Leonardis, Daniela
    Fusaro, Maria
    Tripepi, Giovanni
    Roumeliotis, Stefanos
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2021, 2021
  • [6] Consequences of Delayed Treatment Effects on Analysis of Time-to-Event Endpoints
    Gil D. Fine
    Drug information journal : DIJ / Drug Information Association, 2007, 41 : 535 - 539
  • [7] Familywise error for multiple time-to-event endpoints in a group sequential design
    Thomsen, Henrik F.
    Lausvig, Nanna L.
    Pipper, Christian B.
    Andersen, Soren
    Damgaard, Lars H.
    Emerson, Scott S.
    Ravn, Henrik
    STATISTICS IN MEDICINE, 2024, 43 (18) : 3417 - 3431
  • [8] Trial Design with Win Statistics for Multiple Time-to-Event Endpoints with Hierarchy
    Barnhart, Huiman X.
    Lokhnygina, Yuliya
    Matsouaka, Roland A.
    Rockhold, Frank W.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2024,
  • [9] Consequences of delayed treatment effects on analysis of time-to-event endpoints
    Fine, Gil D.
    DRUG INFORMATION JOURNAL, 2007, 41 (04): : 535 - 539
  • [10] Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies
    Thompson, Simon
    Kaptoge, Stephen
    White, Ian
    Wood, Angela
    Perry, Philip
    Danesh, John
    INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2010, 39 (05) : 1345 - 1359